TMCnet News
Markettelegraph.com: Medical News Flash!(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:23022009 Boston, MA -- Lifespan Inc. (PINKSHEETS: LSPN); Solos Endoscopy, Inc. (PINKSHEETS: SNDY); Cell Therapeutics, Inc. (NASDAQ: CTIC) (MTA: CTIC); Generex Biotechnology Corporation (NASDAQ: GNBT) MarketTelegraph.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our newsletter. Companies wanting to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420. Stock Profiler is pleased to introduce Lifespan Inc. (PINKSHEETS: LSPN) to the investment community. Please visit us at www.stockprofiler.us for more detailed information. ------------------------------------------- Lifespan Inc. closed at $0.04 Friday, trading 115,000 shares. Company News- February 23, 2009: Lifespan Prescribes Medical Technology Injection Lifespan Inc. (PINKSHEETS: LSPN), in furthering its mission to discover, acquire and develop technologically advanced products, announced earlier today it has been approached by a major partner wishing to assist in the implementation of the home based medical testing systems and electronic medical record (EMR) technology previously acquired by the Company and currently described as the 'Advanced Medical division'. To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link. About Lifespan Inc. The Lifespan Corporation was created to develop and guide feasible, economically viable business projects to a profitable and timely conclusion. Advanced Medical Devices is a project that Lifespan acquired several years ago and has been in development for over 10 years. Developments in technology and the US Healthcare industry have now reached a point where this innovative project is ready for launch. For more information, please visit lifespaninc.com. ------------------------------------------- Solos Endoscopy, Inc. closed at $0.0009 Friday, trading 500,000 shares. Company News- February 19, 2009: Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine Solos Endoscopy, Inc. (PINKSHEETS: SNDY) announced Thursday that the Company's breast endoscopy product line, the MammoView(TM), was featured in the "Cover Products" section of Surgical Products Magazine in the December 2008 issue. The article focused on the MammoView(TM)'s functionality that allow Physicians direct visualization, while examining lesions in the mammary ducts. To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link. About Solos Endoscopy, Inc. Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Additional information is available on the Company's website at: www.solosendoscopy.com. ------------------------------------------- Cell Therapeutics, Inc. closed at $0.0535 Friday, trading 3,708,200 shares. Company News- February 20, 2009: Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million Cell Therapeutics, Inc. (CTI) (NASDAQ: CTIC) (MTA: CTIC) announced Friday that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com. ------------------------------------------- Generex Biotechnology Corporation closed at $0.22 Friday, trading 1,275,900 shares. Company News- February 20, 2009: Note to A-Rod: BaBOOM!(TM) is Legal and We'll Give It to You for Free Generex Biotechnology Corporation (NASDAQ: GNBT) the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced Friday it reminds A-Rod and all those looking for a performance-enhancing edge that Generex's BaBOOM!(TM) Energy Spray is available - legally - at convenience stores and drug stores and online at www.baboomenergyspray.com. To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link. About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. For more information, visit the Generex website at http://www.generex.com. ------------------------------------------- The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. MarketTelegraph.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.businessnetwire.us, www.financialbusinessnews.us, www.fastmoneytalk.com, www.associatesfortune.com, www.thewallstreetleader.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us. Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage CONTACT: MarketTelegraph.com e-mail: [email protected] Tel: +1 603 424 4420 WWW: http://www.markettelegraph.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2009 M2 Communications Ltd. |